



23rd Oct 2019

Cyfuse Biomedical K.K.

**Cyfuse Biomedical start promotion of New Bio 3D Printer
through business partnership with Marubeni Corporation**

Cyfuse Biomedical (Headquarters: Bunkyo Ward, Tokyo, CEO: Shizuka Akieda, hereinafter referred to as "Cyfuse") announced today that it has entered into an business partnership agreement with Marubeni Corporation (Headquarters: Tokyo, Japan; President Masumi Kakinoki, hereinafter referred to as "Marubeni") regarding global expansion of a new Bio 3D printer S-PIKE[®] that Cyfuse has developed and commercialized.

Cyfuse is pleased to start promoting of this new Bio 3D printer S-PIKE[®] to the global market together with Marubeni. Cyfuse aim to expand dissemination of platform technology (*1) and accelerate research and development for researchers of regenerative and cell medicine with this S-PIKE[®] which implements a new technology (*2).

Cyfuse will expand dissemination of platform technology with S-PIKE[®] in addition to the Bio 3D printer "Regenova[®](*3), which has been used by a wide range of users.

Cyfuse expect that it will greatly contribute to dissemination of our platform technology to new users, develop new seeds then connect to cell product development by further advancing the global expansion of "S-PIKE[®]".

Marubeni has wide variety of business such as Food, Agriculture&Chemicals, Consumer Products, Power Business, Energy&Metals, Machinery, Infastructure&Financial Business, other related trade (Include Foreign trade), domestic trade, various service, investment and resource development through global network.

Through this business partnership with Marubeni, Cyfuse aim to maximize business synergy by leveraging Marubeni's global business network, know-how and experience as a general trading company. Furthermore, by making practical use of cellular products, Cyfuse aim to create new industry then contribute to the advancement of medical care by enhancing our technologies not only in Japan but also globally.

[Note]

1. Our platform technology is a unique innovative technology that aggregated cells (spheroid) with a diameter of about 0.5 is layered on a fine needle to create a three-dimensional structure only with cells without using scaffold (Invented by Professor Koichi Nakayama of Saga University). This technology is expected that it will make a breakthrough for the regenerative medicine and drug discovery research in a wide range of disease areas.
2. This is a novel three-dimensional cell layering technology which Cyfuse invented and developed. Spheroids is placed on single fine needle, then aligns multiple needles with spheroids. It results to be able to fabricate flexible three-dimensional cell structure.
3. In cooperation with Shibuya Industry Co., Ltd., Cyfuse jointly developed and commercialized a Bio 3D printer "Regenova[®]" which automated platform technology, and has been trying to disseminate platform technology through domestic and overseas sales

[Company Overview]

Cyfuse Biomedical K.K. (hereinafter referred to as "Company") utilizes its unique platform technology of three-dimensionally layered cells to regenerate tissues and organs that malfunction because of disease or injury. Company is established in 2010 with the aim of contributing to save a number of patients in response to meet the unmet medical needs that were not satisfied by existing surgery or treatments.

With its unique three-dimensional cells (Spheroid) layered technology, Cyfuse has been promoting the development for the regeneration of various tissues and organs, such as bone and cartilage, blood vessels, and nerves. At the same time, Cyfuse is putting the technology into practical use as a Drug Screening tool to evaluate the efficacy, toxicity, and metabolism of new drugs.

[Contact]

Cyfuse Biomedical K.K.

2-27-17, Hongo, Bunkyo-ku, Tokyo, 113-0033, JAPAN

Tel : 03-4455-7872

Email : info.jp@cyfusebm.com

URL : <https://www.cyfusebio.com/en/>